Novartis Reports Three-Year ASCLEPIOS Data for Kesimpta in Relapsing Multiple Sclerosis

Novartis today presented three-year follow-up data from the Phase 3 ASCLEPIOS I and II trials evaluating Kesimpta (ofatumumab) in patients with relapsing multiple sclerosis. The data showed that Kesimpta maintained significant reductions in annualized relapse rates and MRI disease activity over three years of treatment. The safety profile remained consistent with previous observations.